News and Events

Upcoming Events

May 2019:

May 3-4, 2019: Dr. Largaespada will be attending the 5th Society for Neuro-Oncology (SNO) Pediatric Neuro-Oncology Basic and Translational Research Conference in San Francisco, CA.

March 2019:

March 29 - April 3, 2019: Dr. Largaespada will be attending the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA. 

News from our Team

February 2019:

Rahrmann EP, Wolf NK, Otto GM, Heltemes-Harris L, Ramsey LB, Shu J, LaRue RS, Linden MA, Rathe SK, Starr TK, Farrar MA, Moriarity BS, Largaespada DA. "Sleeping Beauty Screen Identifies RREB1 and Other Genetic Drivers in Human B-cell Lymphoma." Mol Cancer Res. 2019 Feb; 17(2): 567-582.

January 2019:

Emily Pope, graduate student, was awarded the Dr. Jack Walther Leadership Award at the 2019 Western Veterinary Conference, which is awarded to DVM students for their leadership skills and service to the veterinary profession.

Rathe SK, Popescu FE, Johnson JE, Watson AL, Marko TA, Moriarity BS, Ohlfest JR, Largaespada DA. "Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas." Sci Rep. 2019 Jan 23; 9(1): 358.

Beckmann PJ, Larson JD, Larsson AT, Ostergaard JP, Wagner S, Rahrmann EP, Shamsan GA, Otto GM, Williams RL, Wang J, Lee C, Tschida BR, Das P, Dubuc AM, Moriarity BS, Picard D, Wu X, Rodriguez FJ, Rosemarie Q, Krebs RD, Molan AM, Demer AM, Frees MM, Rizzardi AE, Schmechel SC, Eberhard CG, Jenkins RB, Wechsler-Reya RJ, Odde DJ, Huang A, Taylor MD, Sarver AL, Largaespada DA. "Sleeping Beauty insertional mutagenesis reveals important genetic drivers of central nervous system embryonal tumors." Cancer Res. 2019 Jan 23. Epub ahead of print. 

Smeester BA, Sliped NJ, Pomeroy EJ, Bomberger HE, Shamsan GA, Peterson JJ, Crosby MR, Draper GM, Becklin KL, Rahrmann EP, McCarthy JB, Odde DJ, Wood DK, Largaespada DA, Moriarity BS. "SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis." bioRiv.doi: https://doi.org/10/1101/520452

December 2018:

Li XX, Lu XY, Zhang SJ, Chiu AP, Lo LH, Largaespada DA, Chen QB, Keng VW. "Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation." Biomed Pharmacother. 2018 Dec 18; 111: 68-75. Epub ahead of print.

Slipek NJ, Varshney J, Largaespada DA. "CRISPR/Cas9-Based Positive Screens for Cancer-Related Traits." Methods Mol Biol. 2019; 1907: 137-144.

Fan Y, Bazai SK, Daian F, Arechederra M, Richelme S, Temiz NA, Yim A, Habermann BH, Dono R, Largaespada DA, Maina F. "Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis." J Hepatol. 2019 Mar; 70(3): 470-482. Epub 2018 Dec. 6

November 2018:

November 15-18, 2018: Dr. Largaespada attended Society for Neuro-Oncology's (SNO) 23rd Annual Scientific Meeting in New Orleans, Louisiana.

November 2-6, 2018: Dr. Largaespada, along with several members of his lab attended the 2018 Children's Tumor Foundation NF Conference in Paris, France.

October 2018:

Isakson SH, Rizzardi AE, Coutts AW, Carlson DF, Kirstein MN, Fisher J, Vitte J, Williams KB, Pluhar GE, Dahiya S, Widemann BC, Dombi E, Rizvi T, Ratner N, Messiaen L, Stemmer-Rachamimov AO, Fahrenkrug SC, Gutmann DH, Giovannini M, Moertel CL, Largaespada DA, Watson AL. "Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1." Commun Bio. 2018 Oct 2; 1:158.

August 2018:

August 29, 2018: Dr. Largaespada gave presentation titled "Transposon and targeted nuclease tools for modeling and understanding NF1 syndrome-associated nervous system tumors" at the Sanford School of Medicine Research Seminar in Sioux Falls, SD.

May 2018:

Razzoli M, Nyuyki-Dufe K, Gurney A, Erickson C, McCallum J, Spielman N, Marzullo M, Patricelli J, Kurata M, Pope EA, Touma C, Palme R, Largaespada DA, Allison DB, Bartolomucci A. "Social stress shortens lifespan in mice." Aging Cell. 2018 May 28.

May 22, 2018: Dr. Largaespada gave presentation titled "Genetic pathways of hepatocellular carcinoma development operative in the fatty liver microenvironment" at the Midwest Tumor Microenvironment Conference in Iowa City, IA.

May 3, 2018: Dr. Largaespada gave presentation titled "Exploring the roles of chemotherapy, antigen-specific ex vivo memory T cell expansion, and non-sense codon suppression in immunotherapy" at the 2018 Center for Immunotherapeutic Transport Oncophysics (CITO) Spring Symposium in Houston, TX.

April 2018:

April 14, 2018: Dr. Largaespada gave presentation titled "Uncovering context ddependent drivers in embryonal brain tumors using transposon modeling" during the Education Session at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL. 

April 20, 2018: Dr. Largaespada gave presentation titled "Understanding childhood embryonal brain tumors using transposon-based tools and targeted nucleases" at the International Rhabdoid Tumor Meeting in Alberta, Canada.

February 2018: 

Brenda Weigel, MD, MsC, Brendan Moriarity, PhD, and David Largaespada, PhD highlighted in an article "A new cancer treatment is in clinical trial thanks to Zach Sobiech fund", which was featured in the Pioneer Press and the Bemidji Pioneer on February 12, 2018. 

December 2017:

Beginning in December 2017, David Largaespada will become the Director of the Center for Genome Engineering (CGE). 

November 2017:

Kurata M, Yamamoto K, Moriarity BS, Kitagawa M, Largaespada DA. "CRISPR/Cas9 library screening for drug target discovery." J Hum Genet. 2017 Nov 20. Epub ahead of print. 

Carlson M, Watson AL, Anderson L, Largaespada DA, Provenzano PP. "Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors." J Biomed Opt. 2017 Nov; 22(11): 1-9. 

October 2017:

October 25, 2017: Dr. Largaespada was renewed as an American Cancer Society Research Professor and will be highlighted in the October edition of the Institute for Engineering in Medicine Newsletter.

Scott MC, Temiz NA, Sarver AE, LaRue RS, Rathe SK, Varshney J, Wolf NK, Moriarity BS, O'Brien TD, Spector LG, Largaespada DA, Modiano JF, Subramanian S, Sarver AL. "Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression and survival in osteosarcoma." Cancer Res. 2017 Oct 24. Epub ahead of print.

BT5K LogoOctober 14, 2017: Dr. Largaespada joined several members from the University of Minnesota Brain Tumor Program at the ABTA's BT5K around Lake Como. View information on our team website

 

 

Tschida BR, Temiz NA, Kuka TP, Lee LA, Riordan JD, Tierrablanca CA, Hullsiek R, Wagner S, Hudson WA, Linden MA, Amin K, Beckmann PJ, Heuer RA, Sarver AL, Yang JD, Roberts LR, Nadeau JH, Dupuy AJ, Largaespada DA. "Sleeping Beauty insertional mutagenesis in mice identifies drivers of steatosis-associated hepatic tumor." Cancer Res. 2017 Oct 9. Epub ahead of print.

October 2-4, 2017: Dr. Largaespada attended the Annual Synodos Meeting in Palm Beach, Florida. 

September 2017:

Riordan JD, Feddersen CR, Tschida BR, Jackson P, Keng VW, Linden MA, Amin K, Stipp CS, Largaespada DA, Dupuy AJ. "Chronic liver injury alters driver mutation profiles in hepatocellular carcinoma." Hepatology, 2017 Sep 29. Epub ahead of print

September 28, 2017: Dr. Largaespada presented “Transposon-Based Mouse Models for Finding Drivers of Specific Cancer Behaviors” as part of the Development & the Pathogenesis of Disease Series at the University of Kansas Medical Center, Kansas City, KS.

September 24-27, 2017: Dr. Largaespada presented a talk at Advances in Modeling Cancer in Mice: Technology, Biology and Beyond which is an AACR Special Conference in Orlando, Florida. 

September 21-23, 2017: Dr Largaespada along with Kyle Williams, Mark Sokolowski, Sara Isakson, Bryant Keller, and German Velez Reyes attended the Sarcoma in Neurofibromatosis Retreat at the Marine Biology Laboratory in Woods Hole, MA along with several collaborators in the Nancy Ratner lab from the Cincinnati Children's Hospital.

Kawakami K, Largaespada DA, Ivics Z. "Transposons as tools for functional genomics in vertebrate models." Trends Genet. 2017 Sep 6. Epub ahead of print.

Kyle Williams, PhD, postdoctoral fellow in David Largaespada's laboratory and past Cancer Biology Training Grant member, was named a Children's Tumor Foundation Young Investigator and awarded a two-year fellowship for the study of nervous system tumors associated with Neurofibromatosis Type 1.

August 2017:

Chainbreaker LogoAugust 11-13, 2017: The Largaespada lab participated in Chainbreaker: A Movement to End Cancer. They  created a Peloton (team) called The Little Ras-Cals, which had 16 riders and raised $10,739. All funds were donated to cancer research at the Masonic Cancer Center, University of Minnesota. Members of the team included: David Largaespada, R. Scott McIvor, Zohar Sacks, Kyle Williams, Robin Williams, Flavia Popescu, Germán Vélez Reyes, Sara Isakson, Emily Pomeroy, Nicholas Slipek,  Alex Larsson, Jason Ostergaard, Samual Finnerty, Kyle Meek, Kevin Osum, and Steve Sanderson. View their peloton at The Little Rascals page.    

August 7, 2017: Dr. Largaespada was invited to give a seminar titled "Tracking Down Cancer Using Transposon Mutagenesis and Targeted Nucleases” at Genentech, San Francisco, CA.

July 2017:

July 29, 2017: The lab enjoyed the 10th Annual Largaespada Lake Party at Lake Washington.

July 18-20, 2017: Dr. Largaespada was an invited speaker at the 5th Annual Tumor Models Boston Summit, Boston, MA, "Pre-clinical mouse models of cancer via transposon-mediated mutagenesis or gene transfer."

June 2017:

Dr. Largaespada received a grant from The Sarcoma Foundation of Americaon mechanisms of osteosarcoma chemotherapy resistance titled "Identifying Chemoresistance Pathways in Osteosarcoma".

Dr. Largaespada received a 2017 CCRF Research Grant Award on osteosarcoma titled "Molecular and cellular determinants of metastatic osteosarcoma chemoresistance

Kyle Williams PhD received the Children's Tumor Foundation Young Investigator Award and Fellowship. This is a two year appointment, working to identify novel therapeutic targets and develop treatments for use against NF1-associated tumors and malignancies.

June 23, 2017: Dr. Largaespada was invited to give a special seminar titled "Transposon-Based Mouse Models for Finding Drivers of Specific Cancer Behaviors" at The Hong Kong Polytechnic University, Department of Applied Biology and Chemical Technology, Kowloon, Hong Kong.

June 19-22, 2017: Dr. Largaespada was an invited speaker at the 4th Macau Symposium on Biomedical Sciences.  “Transposon-Based Mouse Models for Finding Drivers of Specific Cancer Behaviors.” Macau, China.

 June 10-13 2017: Dr. Largaespada served on the review committee to score the basic science abstracts at the 2017 Children's Tumor Foundation Neurofibromatosis Conference, in Washington D.C.

Oral Presentations from members at Children's Tumor Foundation Neurofibromatosis Conference:

  • Exploiting novel vulnerabilities in NF1-associated tumorigenesis: A small molecule screen identifies compounds capable of selectively killing NF1 deficient human Schwann cells.
    • Kyle B Williams PhD1, Rory L Williams BS1, Sam A Finnerty BS1, Adrienne L Watson PhD2, Sue Rathe PhD1, Jon Hawkinson PhD1, Gunda Georg PhD1, Christopher L Moertel MD1, David A Largaespada PhD11University of Minnesota, 2Recombinetics Inc.
  • A Swine Model of Neurofibromatosis Type I
    • Adrienne L Watson PhD2, Sara Isakson DVM1, Alex Coutts BS2, Kyle Williams PhD1, Rory Williams BS1, Daniel F Carlson PhD2, Christopher L Moertel MD1, Scott C Fahrenkrug2, David A Largaespada PhD11University of Minnesota, 2Recombinetics Inc.

Poster Presentations from members at Children's Tumor Foundation Neurofibromatosis Conference:

  • Perturbation of the Hyaluronan-Rich Nerve Sheath Tumor Microenvironment to Improve Drug Efficacy and Delivery
    • Bryant J Keller BS1, Adrienne Watson PhD2, Kyle Williams PhD1, Rory Williams BS1, Leah Anderson BS1, Marjorie Carlson BS1, Justin Knight BS1, Colleen Forster BS3, Kwangmin Choi BS4, Nancy Ratner PhD4, Co-Senior: Paolo Provenzano PhD1, Co-Senior: David Largaespada PhD1. Affiliations: 1University of Minnesota, 2Recombinetics Inc., 3BioNet, 4Cincinnati Children's Hospital

June 17, 2017: Several members of lab joined the University of Minnesota Brain Tumor Program attended the Annual Step Up for NF Fundraiser Walk hosted by NF Upper Midwest at Lake Como.

Pomeroy EJ, Lee LA< Lee RDW, Schirm DK, Temiz NA, Ma J, Gruber TA, Diaz-Flores E, Moriarity BS, Downing JR, Shannon KM, Largaespada DA, Eckfeldt CE. "Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia." Oncogene. 2017 Jun 8; 36(23): 3263-3273.

May 2017:

David Largaespada PhD, Kyle Williams PhD, and Germán Vélez Reyes traveled to Cincinnati to meet with our long-term collaborator Dr. Nancy Ratner and the members of her team.

Paul JA, Aich A, Abrahante JE, Wang Y, LaRue RS, Rathe SK, Kalland K, Mittal A, Jha R, Peng F, Largaespada DA, Bagchi A, Gupta K. "Transcriptomic analysis of gene signatures associated with sickle pain." Sci Data. 2017 May 16; 4:170051. 

2016:

The University of Minnesota group of researchers that are one of three consotia for the Children's Tumor Foundation Synodos for NF1 were highlighted in a video on the CTF website

Sachs Z, Been RA, DeCoursin KJ, Nguyen HT, Mohd Hassan NA, Noble-Orcutt KE, Eckfeldt CE, Pomeroy EJ, Diaz-Flores E, Geurts JL, Diers MD, Hasz DE, Morgan KJ, MacMillan ML, Shannon KM, Largaespada DA, Wiesner SM. "Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency." Haematologica. 2016 Oct; 101(10): 1190-1199.

Morrissy AS, Largaespada DA, et al. "Divergent clonal selection dominates medulloblastoma at recurrence." Nature. 2016 Jan 21; 529(7586): 351-357.